stock logo

46% Buy

Natco Pharma Share Price

NATCOPHARM

₹1,020.20-₹4.90 (-0.48%) TodayLast updated on 24 May, 2024 | 03:55 PM IST
₹1,012.00₹1,037.40
L
Show Current Price
H
  • News

  • Company overview

  • Fundamentals

  • Events

  • More

Company overview

Financial performance

arrow

Market cap

Market Cap Switch₹18,273 Crs

Open

₹1,020.00

Close

₹1,025.10

Circuit range

₹1,230.10 - ₹820.10

Day range

₹1,012.00 - ₹1,037.40

Year range

₹609.15 - ₹1,108.35

Volume

8,58,875

Avg. traded

₹1,029.30

Revenue (12m)

₹3,828 Crs

Natco Pharma

Natco Pharma is a Hyderabad-based pharmaceutical company. Natco Pharma is a major manufacturer of branded oncology and Hepatitis C drugs in India. The company is well-known for producing affordable anti-cancer medicines.

Natco is into the production of finished dosage formulations, Active Pharmaceutical Ingredients (API) and crop health science products. The company, listed on both BSE and NSE, has expertise in the development, manufacturing and marketing of complex pharmaceuticals that focus on specific therapeutic areas. Natco specialises in catering to niche markets and offering solutions to address complex medical needs.

The company also provides contract manufacturing services.

Natco Pharma started its journey in 1981 with an initial investment of ₹33 lakh and 20 employees. It started the pharma division at Kothur, Mahaboobnagar, in Telangana. In 1986 it launched a parental manufacturing facility at Nagarjuna Sagar in Telangana. It launched the chemical division in 1993 and started the research division in Hyderabad in 1996. Natco launched the oncology division in 2003.

In a key development, Natco in 2012 received the compulsory licence from the Government of India for the patent-protected anti-cancer drug Nexavar of Bayer. The company launched the crop health sciences division in 2019.

Natco at present has eight manufacturing facilities, including six formulations facilities across India. The plants are equipped with modern research laboratories, capabilities in New Drug Development, etc. Natco currently has around 4500 employees.

Natco Pharma market capitalisation stood at over ₹15,500 crore as of January 30, 2024. Natco Pharma share price has surged more than 63% in the last three years.

Natco Pharma business operations

Natco Pharma markets and distributes products in more than 50 countries. It markets FDF products in the United States, India, Europe and the rest of the world.

Natco Pharma is primarily involved in the development, manufacturing and marketing of finished dosage formulations and active pharmaceutical ingredients. It has four main business segments— formulations, API manufacturing, contract manufacturing and crop health science division.

Formulations Segment

Natco focuses on niche therapeutic areas and complex products. Under its domestic formulations business, the company produces oncology products which include haemato-oncology and solid tumor products. It also produces speciality pharma catering to Orthopaedics and Gastroenterology. The orthopaedics range includes Bisphosphonates – the oral and injectable drugs. Under the gastroenterology division, it produces drugs for Chronic Hepatitis-B.

The company entered the Cardiology and Diabetology segment in 2017. The product range includes anti-hypertensives including Cilnidipine and its combinations (NATCOCIL & range). These are the first line of treatment of hypertension, Ivabradine (IVABRATCO) for stable angina and CHF.

The company’s international formulations business spans the US, Canada, Europe and Brazil. Sun-Ranbaxy, Alvogen, Aceto-Rising, Mylan, Teva, Lupin, Actavis, Breckenridge Pharmaceuticals and DRL are among the key partners of the company in the US market.

Active Pharmaceutical Ingredients

Natco has the expertise of over two decades in the development and commercialising niche APIs. It produces more than 50 APIs while Oncology remains its key therapeutic domain. API portfolio also includes Central Nervous System (CNS), pain management and CV care.

It has two API manufacturing facilities at Chennai and Makeguda that are approved by global health regulators such as USFDA, TGA, Hamburg Health Agency, PMDA, and KFDA.

Contract Manufacturing

Natco also provides contract manufacturing services to many leading pharmaceutical firms in India. Natco currently contract manufactures more than 40 products. These include Azacitidine, Bendamustine HCL, Bortezomib, Capecitabine and Desiferox.

Crop Health Sciences

Natco is looking to expand into the agrichemical space. Natco is focusing on a unique set of molecules for the Indian market, which has the potential to expand to other regions. It has formed strategic alliances with other pharma companies for making inroads into the segment. The activities have been initiated for both active ingredient and crop protection products.

Financial Highlights

  • The company reported consolidated revenue of ₹2,811.7 crore in FY23, up 37.6% year-on-year compared to ₹2043.8 crore in FY22.
  • Its profit after tax (PAT) increased multifold to ₹715.3 crore in FY23 as against ₹170 crore in FY22.
  • The company’s earnings before interest, tax, depreciation and amortisation (EBITDA) surged to ₹1,040.2 crore in FY23 compared to ₹362.5 crore in FY22.
  • The company’s earnings per share (EPS) stood at ₹39.18 in FY23 as against ₹9.32 in FY22.

Natco Pharma Key indicators

arrow

52 week high

₹1,108.35

52 week low

₹609.15

P/E ratio

14.4

P/B ratio

3.17

ROE

14.33%

ROCE

16.51%

Dividend yield

0.56%

Debt/Equity ratio

0.03

EPS

34.91

Learn more

Investment checklist: (2/6)

arrow
check status

Equity returns

check status

Dividend returns

check status

Safety factor

check status

Growth factor

check status

Debt vs Equity

check status

Profit factor

The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily

Analyst ratings:

Buy

arrow

Buy

46%

Hold

31%

Sell

23%

This analysis is based on the reviews of 13 experts in the last 7 days

Fundamentals

Financial ratios

arrow
  • Profitability

  • Operational

  • Valuation

Operating profit margin

38.8%

Net profit margin

26.57%

ROE

14.33%

ROA

12.29%

ROCE

16.51%

Learn more

Natco Pharma Shareholder returns

arrow

1 day

+2.20%

1 week

+2.63%

1 month

+0.22%

3 months

-0.25%

1 year

+65.31%

3 years

+3.54%

5 years

+100.39%

Revenue statement

All values are in ₹ Crores (Cr)
arrow

Cash flow

All values are in ₹ Crores (Cr)
arrow

Balance sheet

All values are in ₹ Crores (Cr)
arrow

Natco Pharma Share Price history

arrow
DayOpenCloseDay’s change
Fri, May 24 2024
₹1,020.00
₹1,020.20
-0.48%
Thu, May 23 2024
₹1,011.80
₹1,025.10
+2.20%
Wed, May 22 2024
₹998.00
₹1,003.05
+0.39%
Tue, May 21 2024
₹1,000.00
₹999.20
-0.02%
Sat, May 18 2024
₹998.00
₹999.40
+0.43%
Fri, May 17 2024
₹1,002.00
₹995.10
-0.38%
Thu, May 16 2024
₹990.00
₹998.85
+1.62%
Wed, May 15 2024
₹993.00
₹982.90
-0.71%

Shareholding info

arrow

Promoters (49.71%)

Mutual Funds (4.08%)

Retail and other (24.46%)

Foreign institutions-FII (16.14%)

Other domestic institutions (5.62%)

Promoters

Learn more

Events

Corporate actions

arrow
  • Dividend • ₹1.25/share

    Ex date 26 Feb 2024

    expand tab
  • Dividend • ₹1.25/share

    Ex date 24 Nov 2023

    expand tab
  • Dividend • ₹7/share

    Ex date 22 Aug 2023

    expand tab
  • Dividend • ₹1.25/share

    Ex date 21 Feb 2023

    expand tab
  • Dividend • ₹0.75/share

    Ex date 21 Nov 2022

    expand tab
  • Dividend • ₹3.5/share

    Ex date 19 Aug 2022

    expand tab
  • Dividend • ₹2/share

    Ex date 24 Feb 2022

    expand tab
  • Dividend • ₹0.5/share

    Ex date 23 Nov 2021

    expand tab

Learn more

Frequently asked questions